Ariad Drug Appears To Delay Lung Cancer's Return Longer Than Rival Medicines
Ariad Pharmaceuticals’ experimental drug to treat patients with non-small cell lung cancer who’ve stopped benefiting from Pfizer’s Xalkori seems to work longer than other options, and may be better at affecting tumors that have spread to the brain, according to new data to be presented here at the American Society of Clinical Oncology this morning.
21Vianet announces $388 mln investment from Tus-Holdings at $16.274/share (VNET) :
The co announced that Tus-Holdings Co., Ltd., a large integrated enterprise established in reliance on Tsinghua University, has, through its affiliated investment vehicle, entered into definitive share subscription agreement to make $388 million equity investment in the Company.
Pursuant to the Share Subscription Agreement, an affiliated investment vehicle of Tus-Holdings will make a US$388 million investment in 21Vianet, with a share subscription price of approximately $2.712 per ordinary share, or $16.274 per ADS. The investment will be comprised of newly issued 31,996,874 Class A ordinary shares and 111,053,390 Class B ordinary shares. Immediately after the closing of the transaction, Tus-Holdings will, through its affiliated investment vehicle, hold approximately 21.4% equity ownership in 21Vianet, representing approximately 51.0% of the voting power.
They own about 36 percent of the shares
The 35 analysts offering 12-month price forecasts for Nokia have a median target of $7.74, a solid 49.3% upside from current levels.
They are "Very Poor Examples" of people that should be in charge of growing a company...PATHETIC!